A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Trial Profile

A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Tivozanib (Primary)
  • Indications Soft tissue sarcoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Mar 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2018.
    • 22 Oct 2016 Primary endpoint has been met. (Progression-free survival from study disease will be evaluated using imaging scans (CT or MRI)), according to results published in the Annals of Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top